Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study...

  • Main
  • 2020 / 03
  • Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study...

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai, Jayesh, Gan, Hui, Barrow, Catherine, Jameson, Michael, Atkinson, Victoria, Haydon, Andrew, Millward, Michael, Begbie, Stephen, Brown, Michael, Markman, Ben, Patterson, William, Hill, Andrew, Ho
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.19.02654
Date:
March, 2020
File:
PDF, 791 KB
english, 2020
Conversion to is in progress
Conversion to is failed